Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcellx, Inc. - Common Stock
(NQ:
ACLX
)
66.12
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Arcellx, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
October 17, 2023
Via
Benzinga
Analyst Ratings for Arcellx
June 20, 2023
Via
Benzinga
Why Arcellx (ACLX) Stock Is Nosediving
June 20, 2023
Arcellx Inc (NASDAQ: ACLX) shares are trading lower by 8.50% to $32.76 Tuesday morning after the FDA on Monday put a clinical hold on the company's multiple myeloma phase 2 trial.
Via
Benzinga
The Latest Analyst Ratings for Arcellx
May 18, 2023
Via
Benzinga
Where Arcellx Stands With Analysts
April 24, 2023
Via
Benzinga
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
October 02, 2023
CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T.
Via
InvestorPlace
Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential
August 15, 2023
The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 Clinical Program.
Via
Benzinga
Exposures
Product Safety
FDA Gives Green Signal To Arcellx's Stopped Blood Cancer Study
August 15, 2023
The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Monday's After-Market Session
August 14, 2023
Via
Benzinga
Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death
June 20, 2023
A patient died in Arcellx's multiple myeloma drug study. But the underlying factors are complex.
Via
Investor's Business Daily
What 5 Analyst Ratings Have To Say About Arcellx
March 30, 2023
Via
Benzinga
Where Arcellx Stands With Analysts
December 12, 2022
Via
Benzinga
Why Is Arcellx (ACLX) Stock Up 25% Today?
December 09, 2022
ACLX stock is usually under the radar, but today it's in the spotlight as Arcellx reveals a team-up with a well-known biotech business.
Via
InvestorPlace
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
June 20, 2023
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740.
Via
Benzinga
Arcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls
June 20, 2023
The FDA has put a clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 clinical program for CART-ddBCMA investigational new drug for
Via
Benzinga
Why Cano Health Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
June 20, 2023
Gainers
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
June 20, 2023
It's time for another dive into the biggest pre-market stock movers as we check out all the latest news for Tuesday morning!
Via
InvestorPlace
Alibaba, Arcellx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
June 20, 2023
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
May 18, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2023
April 14, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023
March 14, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 13, 2023
February 13, 2023
Via
Benzinga
20 Favorite Biotech & Medical Stocks For 2023
December 28, 2022
The way these stocks are setting up, many of them look great and will be at the forefront this coming year.
Via
Talk Markets
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
December 19, 2022
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Via
Benzinga
Dow Tumbles 100 Points; Silver Rises Over 2%
December 09, 2022
U.S. stocks traded mostly lower toward the end of trading with the Dow Jones dropping 100 points on Friday
Via
Benzinga
Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session
December 09, 2022
Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.
Via
Benzinga
US Stocks Turn Higher; Nasdaq Rises 40 Points
December 09, 2022
U.S. stocks traded slightly midway through trading with the Nasdaq gaining over 40 points on Friday
Via
Benzinga
Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences
December 09, 2022
The company inked a deal worth $325 million and up to $3.9 billion in milestones.
Via
Investor's Business Daily
US Stocks Edge Lower; Producer Prices Increase Higher Than Expected
December 09, 2022
U.S. stocks traded slightly lower this morning following the release of PPI data
Via
Benzinga
Gilead's Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate
December 09, 2022
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.